EPFL-founded tissue analysis technology developer Lunaphore has now raised $37.3m in all after a series C round led by medical products firm PHC Holdings.

Lunaphore, a Switzerland-based cancer research and diagnostics spinout of École Polytechnique Fédérale de Lausanne, yesterday revealed it had raised an initial CHF23m ($23.6m) in series C funding led by healthcare group PHC Holdings.
The transaction, completed on January 15, also feature venture capital firm Redalpine Venture Partners, investment firm Alpana Ventures and investment group Occident.
Founded in 2014, Lunaphore has developed a human tissue analysis system for cancer research and pathological studies.
The spinout’s flagship product, LabSat…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?